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AbstrAct
Objective Cardiac resynchronisation therapy (CRT) is an 
effective therapy for selected patients with heart failure 
(HF); however, a significant non-response rate exists. We 
examined current evidence on extracellular cardiac matrix 
(ECM) biomarkers in predicting response following CRT.
Methods Complete literature review of PubMed, Ovid 
SP MEDLINE, Cochrane Library and TRIP, reference lists, 
international cardiology conferences and ongoing studies 
between December 1999 and December 2015 conducted 
according to prospectively registered study selection and 
analysis criteria (PROSPERO:CRD42016025864) was 
performed. All observational and randomised control 
trials (RCT) were included if they tested prespecified ECM 
biomarkers’ ability to predict CRT response. Risk of bias 
assessment and data extraction determined pooling of 
included studies was not feasible due to heterogeneity of 
the selected studies.
Results A total of 217 studies were screened; six (five 
prospective cohort and one RCT substudy) were included 
in analysis with 415 participants in total. Study sizes 
varied (n=55–260), cohort characteristics contrasted 
(male: 67.8%–83.6%, ischaemic aetiology: 40.2%–
70.3%) and CRT response definitions differed (three 
clinical/functional, three echocardiographic). Consistent 
observation in all ECM biomarker behaviour before and 
after CRT implantation was not observed between studies. 
Lower type I and type III collagen synthesis biomarkers 
(N-terminal propeptides of type I and III procollagens) 
expression demonstrated replicated ability to predict 
reverse left ventricular remodelling.
Conclusion Collagen synthesis biomarkers offer the most 
potential as ECM biomarkers for predicting CRT response. 
Heterogeneity between these studies was large and 
limited the ability to pool and compare results numerically. 
Use of different response definitions was one of the 
biggest challenges.
IntROduCtIOn
Cardiac resynchronisation therapy (CRT) 
is an effective therapy for selected patients 
with heart failure (HF).1 2 Current guide-
lines suggest that CRT is offered to those 
with a left ventricular ejection fraction 
(LVEF) ≤35% with resting 12-lead ECG QRS 
duration ≥150 ms or 120–149 ms with Left 
Bundle Branch Block (LBBB) morphology 
and refractory to optimal medical therapy 
(OMT).3 CRT reduces mortality and 
improves morbidity, underpinned by reversal 
of pathophysiological adverse cardiac 
remodelling.1 2 Unfortunately, a significant 
non-response rate of 20%–40% exists and has 
remained unchanged over the last decade, 
despite extensive research and investment.1 2
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Key questions
What is already known about this subject?
 ► Cardiac resynchronisation therapy  (CRT) is 
associated with non-response in 20%–40% of 
selected patients with heart failure (HF). Selected 
vascular biomarkers are known to be associated 
with cardiac disease but it is unknown whether 
these can be used to predict CRT response.
What does this study adds?
 ► We performed a systematic review of all studies 
examining vascular biomarkers in CRT. We 
found that collagen synthesis biomarkers have 
the most potential for predicting CRT response, 
particularly N-terminal propeptides of type I and III 
procollagens. Matrix metalloproteinases-2  and  9 
have no conclusive predictive value and need 
further investigation.
How might this impact clinical practice?
 ► Use of vascular biomarkers to predict CRT 
response could have enormous clinical benefit 
by selectively identifying those patients with 
HF who are likely to benefit. This has important 
implications for both patients and healthcare 
providers worldwide, especially given the current 
financial climate.
Open Heart
2 McAloon CJ, et al. Open Heart 2017;4:e000639. doi:10.1136/openhrt-2017-000639
The extracellular cardiac matrix (ECM) is a dynamic 
support structure that remodels following cardiac injury 
and HF.4 5 Progressive ECM remodelling is closely linked 
to HF severity and prognosis.4 5 Cardiac collagen turnover 
alterations are central to the development and progres-
sion of cardiac fibrosis and HF.5 Specific biomarkers 
of type I and type III collagen synthesis (N-terminal 
propeptides of type I and III procollagens (PINP and 
PIIINP),6 7 carboxy-terminal propeptide of procollagen 
type I (PICP))8 9 and degradation (carboxy-terminal telo-
peptide of type I collagen (ICTP or CITP))9 10 products 
are associated with poor outcomes in HF. The proteolytic 
enzyme system matrix metalloproteinases (MMPs) and 
their regulators tissue inhibitors of MMPs (TIMPs) are 
involved in collagen degradation and have been impli-
cated in HF development and progression.4 5 Specifically, 
MMP-1,11 a collagenase, MMP-212 and MMP-9,13 both 
gelatinases and TIMP-111 are associated with HF outcomes. 
Galectin-3 (Gal-3) is a beta-galactoside-binding lectin 
released by activated cardiac macrophages, which are 
upregulated in HF, causing increased fibroblast prolifer-
ation, collagen deposition and ventricular dysfunction.14 
Gal-3 is strongly associated with inflammation and fibrosis 
with raised levels strongly predict poor HF outcomes.14
Turnover of ECM alters in HF and with reverse cardiac 
remodelling following CRT implantation may offer 
potential biomarkers for response prediction.15 This 
systematic review examines the current evidence on the 
value of ECM biomarkers in predicting CRT response.
MetHOdOlOgy
Our systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guidelines.16 It was prospec-
tively registered with PROSPERO (CRD42016025864), 
an international registry of systematic reviews. A protocol 
was designed and implemented prospectively in-line with 
PRISMA-P 2015.17
eligibility criteria
Strict eligibility criteria were applied to minimise hetero-
geneity of included articles. Observational studies 
(prospective or retrospective) and randomised control 
trials (RCTs) (including substudies) were included; basic 
science and review articles were excluded. Included 
study populations represented patients with HF meeting 
international CRT implant guidelines.3 Studies had to 
be conducted on adults (age ≥18 years). Articles were 
included if they examined an ECM biomarker previ-
ously reported to predict HF outcomes.4 Baseline ECM 
biomarkers, measured when patients were clinically 
stable prior to implantation, had to be compared with 
a predefined CRT ‘response’ criteria to evaluate their 
predictive value. Coronary sinus sampling and long-term 
trends in peripheral ECM biomarker behaviour were 
analysed if present.
A variety of clinical, functional or echocardiographic 
criteria and cardiovascular outcomes have been used to 
define CRT response in studies,18 which often correlate 
poorly. All response criteria were included in the review. 
Cardiovascular outcomes could form part of a response 
definition or be presented separately; their absence was 
not an exclusion criterion.
database search strategies
Detailed searches were conducted on PubMed, Ovid SP 
MEDLINE, Cochrane Library (CENTRAL) and TRIP 
in February 2016 by one author (CM) and reviewed by 
another independently (DA). The search strategy used 
specific terms (cardiac resynchronisation therapy/
cardiac pacing/extracellular matrix) in combination, 
within titles/abstracts or Medical Subject Headings. 
Specific vascular biomarkers (‘TIMP’ ‘MMP’ ‘collagen’ 
‘Myostatin’ ‘Syndecan-4’ and ‘Galectin-3’) were included 
in the search. A grey literature search involved searching 
the Clinical Trials database (www. clinicaltrials. gov) 
and international cardiology conferences (European 
Society of Cardiology, American Heart Association, 
American College of Cardiology) indexes for ongoing, 
abstracts and unpublished work. All included articles 
had their references searched for relevant publications. 
A date limitation of the last 15 years (31 December 1999– 
31 December 2015) was applied. No language restrictions 
were applied.
Title and abstract reviews were performed inde-
pendently (CM/DA), consensus on eligibility criteria was 
required to be taken forward to full paper review; any 
conflicts were decided by an independent reviewer (FO). 
Duplications of articles or cohort use were identified and 
only the most relevant (decided by consensus) taken 
forward. The Critical Appraisal Skills Programme check-
list (dependent on study design) was applied to full paper 
review to guide evaluation of article quality.19 Consensus 
had to be reached on full paper reviews before being 
selected for inclusion; where consensus was not reached 
a third reviewer (FO) made the final decision. Contact 
was attempted with all included article authors and any 
others at full paper review that were indicated.
data extraction and management
Full texts of included articles were obtained. Pilot data 
extraction was performed on two randomly selected 
articles and reviewed for robustness (CM, DA, FO, 
PB). A standardised data extraction form was created 
to collect data on each study’s design (eligibility 
criteria, methodology, assessment period), patient 
population (numbers, age, gender, aetiology, ECG, left 
ventricular (LV) geometry, quality of life, New York 
Heart Association (NYHA), functional assessment), 
vascular biomarker/predictor (specific ECM surrogate 
biomarkers, units, conditions of sampling, laboratory 
assessment, statistical prediction model) and outcome 
(response definition and cardiovascular outcomes). 
Data extraction was performed by two independent 
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Figure 1 Flowchart of studies screening and selection. ≠Author contacted, poster presentation sent and no baseline 
extracellular cardiac matrix biomarker sample taken.22 *Clinical trial (NCT15019908) author contacted and manuscript in 
preparation. CRT, cardiac resynchronisation therapy.
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reviewers (CM/DA), a third independent reviewer 
(FO) resolved any disagreement.
Risk of bias assessment
Risk of bias for each study was assessed by two indepen-
dent reviewers (CM, DA) utilising either the Risk of Bias 
Assessment Tool for Non-randomised Studies or the 
Cochrane Collaboration ‘Risk of Bias’ assessment tool.20 21 
Both have established criteria to examine selection bias, 
exposure measurement, blinding and completeness of 
outcome data.20 21
data synthesis and analysis
A descriptive synthesis was performed to summarise find-
ings of all selected articles. A meta-analysis of included 
study data for each specific ECM biomarker was not 
possible due to heterogeneity of outcome definitions 
and study designs. Evaluation of study designs, defined 
outcomes and cohort characteristics was performed. The 
same biomarkers compared in different included articles 
were compared. Continuous variables were summarised 
using the same units for each variable in the original text. 
Data were presented as mean ± standard deviation (SD), 
unless specified otherwise.
Results
Figure 1 shows the screening and selection of published 
articles; 110 records were excluded after the screening 
stage as they did not meet inclusion criteria. Six articles met 
the inclusion criteria. Two abstracts22 23 and one clinical 
trial entry (www. clinicaltrials. gov) (NCT15019908) were 
Open Heart
4 McAloon CJ, et al. Open Heart 2017;4:e000639. doi:10.1136/openhrt-2017-000639
taken to full review (for potential inclusion). Related arti-
cles and information were sought, including contacting 
authors (all three kindly responded). None yet had arti-
cles published and additional information provided led 
to exclusion from review (no baseline biomarkers taken22 
or study design did not test biomarkers as predictors23).
study design
Five prospective cohort studies and one RCT substudy11 
were included. Table 1 summarise the different study 
designs and CRT response outcome definitions used. 
Studies selected were published between 2008 and 2014. 
Risk of bias was assessed in each study using appropriate 
quality check tools. The lowest risk of bias was in the 
single RCT substudy.11 The prospective cohort studies 
varied minimally in their bias assessment and none were 
excluded.
Garcia-Bolao et al9 stated that 61 participants were 
consented; during the observation period there were 
four mortalities (three cardiac/one non-cardiac) and one 
functional assessment not performed at follow-up (6 min 
walk test not completed due to stroke). The cohort was 59 
but no explicit statement about the two exclusions made. 
Lopez-Andres et al11 published a substudy in 2012 of the 
‘The Effect of Cardiac Resynchronization on Morbidity 
and Mortality in Heart Failure’ (CARE-HF)1 RCT which 
itself was published in 2005; interpretation of results is 
within this context. All studies included NYHA III–IV 
patients (mostly NYHA III). Two studies recruited NYHA 
II patients24 25 with one also requiring a bradycardia 
pacing indication.24 All studies included QRS dura-
tion >120 ms, except Garcia-Bolao et al9 (QRS≥130 ms). In 
the CARE-HF trial, those with QRS duration 120–149 ms 
needed dyssynchrony on echocardiography.1 8 All trans-
venous LV leads were implanted preferably to the most 
lateral position possible. Dong et al26 performed only 
de novo CRT-defibrillator (CRT-d) implants. Three 
studies10 24 26 commented on right ventricular lead place-
ment with two26 explicitly aiming for the right ventricular 
apex. In CARE-HF (and substudy), all had CRT-pace-
maker (CRT-p) devices only.1 11 CRT response definitions 
varied between included studies. Broadly, response defi-
nitions used were classified as three clinical and three 
echocardiographic. Reported response rates varied 
between 48.9% and 71.8% (table 1).
Baseline characteristics
The baseline characteristics of the patients are shown in 
table 2.
A total of 415 patients were included. The five prospec-
tive observational studies had mean age of 67±10 years9 10 
(Lopez-Andres et al8 excluded as presented as median 
and IQR). There were 315 (75.9%) males in included 
studies, ranging 67.8%9–83.6%.25 There was large varia-
tion in frequency of CRT-d/CRT-p implants in each study 
with two not providing this data.10 25 One study included 
a high proportion of device upgrades25; the CARE-HF 
trial excluded upgrades,1 8 the remaining four studies 
did not state upgrade status.9 10 24 26 Atrial fibrillation 
(AF) was included in three prospective observational 
studies8 24 25; one did not report on AF or related publi-
cations.10 27 Precise QRS duration was not stated in two 
studies.24 26 Reporting of LV volumetric data varied 
between included studies. Three reported unadjusted 
LV end systolic volume (LVESV) and LV end diastolic 
volume (LVEDV) data which were similar to each other 
(table 3).10 24 25 Dong et al26 presented LVESV and LVEDV 
volume indexed figures only. Garcia-Bolao et al9 provided 
LVEF only. LVEF was compared between the five prospec-
tive cohorts and showed similar mean LVEF between 
25%–27%.9 10 24–26
Responder versus non-responders
Response status (responders vs non-responders (RvsNR)) 
was presented in four of the included studies.9 10 24 26 
Truong et al25 did not provide characteristics of those 
defined by response. Lopez-Andres et al8 outlined char-
acteristics by allocation to CRT-p versus OMT, however, 
not by response. There were some baseline characteristic 
differences between the four studies for RvsNR9 10 24 26; 
Dong et al26 demonstrated differences between RvsNR 
for LBBB status (15 (68.3%) vs 9 (39.1%), p=0.05) and 
ischaemic aetiology (9 (40.9%) vs 17 (73.9%], p=0.03). 
Tolosana et al24 reported lower creatinine levels in RvsNR 
(1.25±0.3 mg/dL vs 1.76±0.8 mg/dL, p=0.01). Umar et 
al10 reported that responders were older and had longer 
QRS duration than non-responders (age: 66±10 years vs 
60±11 years, p=0.03; mean± standarderror QRS: 165±3 ms 
vs 135±8 ms, p=0.001). Notably, Hessel et al published a 
study using the same cohort as Umar et al and reported 
no difference in QRS duration for RvsNR (165±2 ms vs 
153±3 ms, p=NS), suggesting one of these studies has 
recorded it incorrectly.10 27
eCM biomarkers
All ECM biomarker baseline concentrations and magni-
tude of association (if tested) are summarised in table 3. 
Lopez-Andres et al8 did not provide baseline concentra-
tions by response status, but comparison was made with 
the control group. Umar et al10 showed baseline results 
for expression of ECM biomarkers studied. However, for 
PIIINP non-responders no baseline concentration was 
reported in the article, however no statistical significance 
is reported RvsNR.10
PInP/PICP
PINP and PICP share a 1:1 stoichiometric relationship 
with the collagen molecule; therefore, they were consid-
ered together. Umar et al10 reported similar total cohort 
means values to Lopez-Andres et al8 median values (the 
skew of this data is unknown). Umar et al10 observed 
higher PINP baseline level predicted poor response. 
Garcia-Balao et al9 reported the opposite for PICP. 
Lopez-Andres et al8 observed no significant association 
of baseline PINP with CRT response or other outcomes. 
Variation in the pattern of reported levels between the 
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three studies were likely due to differences in response 
definitions and baseline characteristics. Garcia-Balao et 
al9 utilised a clinical definition of response, whereas the 
other two studies used echocardiographic criteria.8 10 All 
studies varied in duration of follow-up. Umar et al10 had 
a higher proportion of men with ischaemic aetiology 
than the other studies. Lopez-Andres et al8 excluded 
AF, whereas within the Garcia-Balao et al9 cohort it was 
present in 18.6% of participants. Garcia-Balao et al9 tested 
the predictive value of type I collagen turnover with the 
PICP:CITP ratio with a ratio ≥14.4 predicting response.
PIIInP
Variation was reported in trends of PIIINP levels at base-
line. Dong et al26 reported logarithmic figures making 
absolute figure comparison challenging. Geometric 
means could be calculated, but given small numbers 
of participants this was likely to underestimate the 
true mean.26 Higher PIIINP levels in HF versus healthy 
controls (0.88±0.21 ug/L vs 0.71±0.14 ug/L, p=0.01) were 
observed.26 Responders had significantly lower PIIINP 
baseline levels than non-responders (p=0.03).26 Umar 
et al10 demonstrated no difference in baseline levels 
between RvsNR. Lopez-Andres et al8 reported similar 
baseline levels between CRT-p and OMT, but did observe 
PIIINP (>4.7 ug/L) in univariate analysis predicted 
cardiovascular outcomes (death or HF hospitalisation at 
18 months) (OR 1.80, 95% CI 1.06 to 3.06, p=0.03).8
ICtP or CItP
Both ICTP and CITP were used to represent carbox-
yl-terminal peptides of type I collagen in three included 
studies. Umar et al13 and Garcia-Balao et al12 demon-
strated similar baseline means for ICTP/CITP for the 
entire cohort. Neither identified independent predictors 
of CRT response.9 10 Garcia-Bolao et al9 identified that 
the PICP:CITP ratio strongly predicted response but 
was driven by PICP. Lopez-Andres et al8 observed similar 
expression between CRT-p and OMT groups and showed 
no predictive value.
MMP-1, MMP-2 and MMP-9
There were variations in reported baseline concentra-
tions for MMP-1. The mean for MMP-1 in Garcia-Bolao et 
al9 was higher than median observed in CRT-p and OMT 
groups in Lopez-Andres et al,8 though the data skew is 
unknown. Garcia-Bolao et al9 examined the predictive 
value of MMP-1:TIMP-1, given their intrinsic regula-
tory role in collagen turnover,5 but showed no statistical 
significance. Lopez-Andres et al8 observed with a base-
line MMP-1 ≤3 ug/L an adjusted threefold increased risk 
of CRT non-response and an increased risk of death or 
N-terminal pro B-type natriuretic peptide >1000 ng/L 
(OR 2.23, 95% CI 1.00 to 5.00, p=0.051/0.073 adjusted 
with/without renal function).8 A precursor to MMP-1 
called pro-MMP-1 (pro-MMP-1) was studied by Umar et 
al.10 They observed no difference in baseline pro-MMP-1 
expression between RvsNR.10
7McAloon CJ, et al. Open Heart 2017;4:e000639. doi:10.1136/openhrt-2017-000639
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Two studies reported cohort means for MMP-2 base-
line concentration with large differences (table 3). 
Responders had lower MMP-2 baseline concentrations in 
both studies. Tolosana et al24 reported a significant differ-
ence between RvsNR (p=0.02), whereas Garcia-Bolao et 
al9 demonstrated no difference. The differences are not 
fully explained by study design, response definition or 
cohort characteristics as they showed similarities (tables 1 
and 2). Variation in levels may be due to Tolosana et al24 
using plasma and Garcia-Bolao et al9 using serum in their 
sandwich ELISAs. MMP-9 was reported by Garcia-Bolao et 
al,9 who observed a trend towards lower baseline MMP-9 
concentration for Responders. Baseline MMP-9 did not 
predict CRT response.9
tIMP-1
Tolosana et al24 observed that responders had signifi-
cantly lower concentrations at baseline of TIMP-1 than 
non-responders. Neither Umar et al10 nor Garcia-Bolao et 
al9 observed a significant difference in baseline TIMP-1 
concentration between RvsNR. Higher peripheral 
TIMP-1 was identified as an independent predictor of 
non-response by Tolosana et al24 in multivariable analysis; 
a concentration of ≥248 ug/L had a 71% sensitivity and 
72% specificity for predicting non-response. However, 
Umar et al10 did not identify TIMP-1 as a predictor. Garcia-
Bolao et al9 tested TIMP-1 in the MMP-1:TIMP-1 ratio 
and did not identify TIMP-1 as a significant predictor of 
RvsNR.
gal-3
Lopez-Andres et al8 reported higher baseline levels of 
Gal-3 than Truong et al,25 due to different response defi-
nitions and variation in cohort characteristics. Lopez et 
al8 used an echocardiographic definition at 18 months 
and Truong et al25 utilised HF clinical composite score at 
6 months. Truong et al25 has higher ischaemic aetiology 
(53.4% vs 40.2%) and included patients with AF. Neither 
study reported baseline concentrations for RvsNR.8 25 
Truong et al25 observed that peripheral baseline Gal-3 
above a preset concentration (>25.9 ug/L) had low sensi-
tivity and high specificity for predicting CRT response.
dIsCussIOn
The ECM is a highly dynamic structure that is integral 
to myocardial structure and function which detrimentally 
remodels following cardiac injury leading to the altered 
turnover, replacing contractile tissue with collagen rich 
connective tissue and ultimately the development of 
myocardial fibrosis.5 Myocardial fibrosis is characterised 
by adverse remodelling which contributes to systolic 
and diastolic HF.5 28 PINP, PICP and PIIINP are released 
into the circulation during conversion and deposition 
of procollagen to collagen and are upregulated during 
myocardial fibrosis and associated with adverse HF 
outcomes.5 7 15 28 Mechanistically, higher upregulation 
of collagen would challenge a CRT’s ability to reverse 
remodel and for the patient to respond. Umar et al10 
supported this hypothesis observing significantly lower 
baseline PINP expression predicted echocardiographic 
response. Dong et al26 did observe lower baseline PIIINP 
predicted echocardiographic response on univariate 
analysis, but not multivariable analysis. In contrast, 
Garcia-Balao et al9 observed higher baseline expres-
sion of PICP in responders and PICP:CITP ratio (type 
I collagen turnover) of ≥14.4 had greater than twofold 
increased chance of predicting functional response, 
driven by PICP. Critically, echocardiographic and clin-
ical/functional response criteria correlate poorly,18 so 
could not be contrasted. Importantly, Lopez-Andres et al,8 
the largest study included in the review, did not observe 
upregulation of collagen synthesis predicting echocardio-
graphic non-response, which does challenge the Umar et 
al10 and Dong et al26 observations; however, the cohort 
characteristics and study designs were different. The 
observations of collagen synthesis following CRT implan-
tation conflict with each other. Umar et al10 reported a 
significant increase in PINP and decrease in PIIINP 
expression in responders at 6 months; both would mecha-
nistically be expected to be lower at follow-up. In contrast 
Garcia-Bolao et al9 observed PICP levels decreased for 
responders and increased for non-responders at 1 year, 
which would be expected, but is based on a functional 
response definition. In contrast to collagen synthesis, 
degradation biomarkers (ICTP or CITP) did not predict 
CRT response.8–10 Furthermore, no significant change in 
ICTP or CITP expression was observed at follow-up across 
all three studies.8–10 Alteration in collagen synthesis rate 
is observed to be more powerful at predicting response 
than collagen degradation. Different patterns of collagen 
synthesis biomarkers predicting response have been 
observed; lower expression predicted LV reverse remod-
elling,10 26 whereas higher rates predicted functional 
response.9 The variation in these patterns is explained 
by the different response definitions and cohort charac-
teristics. The study cohort for Umar et al10 had a higher 
proportion of men and ischaemic cardiomyopathy than 
Garcia-Bolao et al.9 The heterogeneities between these 
studies make drawing conclusions difficult. Lopez-Andres 
et al8 also challenge any observations due to size of cohort 
and no prediction value to collagen turnover observed. 
Overall, collagen synthesis is observed to be important in 
predicting CRT response, especially LV reverse remodel-
ling, with results replicated in two studies that lower rates 
predict LV reverse remodelling.10 26
MMP-1, MMP-2 and MMP-9 perform a critical role 
in myocardial collagen degradation and have been 
identified as being important prognostic markers in 
HF.11 13 27 Predictive value for CRT non-response (death 
or LVEF ≤35% at 18 months) was only demonstrated in 
baseline MMP-1 expression ≤3 ug/l8 supporting an obser-
vation by Jordan et al11 that lower MMP-1 inferred worse 
HF prognosis. MMP-2 had large variations observed 
between the included studies,8 24 but was not demon-
strated to predict response. MMP-9 was only observed 
in one included study showing no predictive value9; 
9McAloon CJ, et al. Open Heart 2017;4:e000639. doi:10.1136/openhrt-2017-000639
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however, recently Dini et al13 demonstrated raised levels 
(>238 ng/mL) and predicted worse HF outcomes. MMP 
activity was not considered in any of these studies as a 
predictor but would be important to consider in the 
future. Current evidence suggests that MMPs, especially 
MMP-2 and MMP-9, have not yet had their potential fully 
evaluated.
TIMP-1 regulates the endogenous proteolytic MMP 
system involving discordant inhibition and in chronic 
inflammatory states stimulating collagen synthesis and 
myocardial fibrosis.5 24 Tolosana et al24 observed a signif-
icant baseline difference in RvsNR expression with 
lower TIMP-1 in responders. Tolosana et al24 demon-
strated that baseline TIMP-1 (≥248 ug/L) predicted CRT 
non-response. Trucco et al29 in long-term follow-up of 
the same cohort demonstrated that the same threshold 
independently predicted mortality at 60±34 months 
(sensitivity 80% and specificity 71%). Tolosana et al24 also 
demonstrated that statistically significant lower TIMP-1 is 
found in participants that do LV reverse remodel (LVESV 
reduction ≥10%). Umar et al10 and Garcia-Bolao et al9 
observed no difference statistically at baseline. Variation 
between the reported literature in the magnitude of asso-
ciation of TIMP-1 exists; however, Tolosana et al24 offers 
a well-designed prospective observational study which is 
powered giving strength to the conclusions drawn.
Gal-3 stimulates fibroblasts to release TIMPs and MMPs 
that regulate collagen turnover, resulting in myocardial 
fibrosis.14 Elevated levels are independent predictors 
of adverse outcomes in HF.14 Evaluation of Gal-3 as a 
predictor of response was limited, as RvsNR was not 
reported in either of the two studies.8 25 Truong et al25 
demonstrated peripheral baseline Gal-3 ≥25.9 ug/L had 
specificity for predicting CRT response. Lopez-Andres 
et al8 observed Gal-3 baseline expression ≥30 ng/L had 
nearly threefold increased risk of death or hospitalisation 
for worsening HF following CRT. Though not demon-
strated to be a strong predictor, the evidence suggests 
that Gal-3 is a good biomarker for predicting poor 
outcomes in HF and needs further evaluation.
The greatest challenge for research into CRT 
response and one this review demonstrated is lack of 
an accepted response definition. Differing definitions 
rarely correlate,18 which our review clearly demonstrates. 
Echocardiographic and clinical/functional definitions 
correlate very poorly and should never be compared or 
applied in a composite definition18; LV reverse remodel-
ling should be considered separately.18 30
study limitations
Heterogeneity among included studies was widespread 
despite a rigorous eligibility and screening criteria. The 
variations in study design, cohort characteristics and 
response definitions made pooling data in a meta-analysis 
impractical. CRT implantation techniques and indica-
tions have evolved over the last 15 years and offer another 
source of heterogeneity. Furthermore differences in 
laboratory techniques account for some variation among 
biomarker results. These limitations are particularly 
important to consider in future research studies.
COnClusIOns
Collagen synthesis biomarkers have shown the most 
potential, particularly PINP and PIIINP, but will require 
further study. MMP-2 and MMP-9 have no conclusive 
predictive value and need further investigation. Hetero-
geneity is the greatest challenge for research in this field 
and needs to be minimised in future studies. The most 
important initial step is for a universal response defini-
tion to be adopted and applied.
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